A case of “double hit” mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib-Reference-Cited by-同舟云学术

A case of “double hit” mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib

Published:2020-07-15 Issue:11 Volume:99 Page:2715-2717
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Scapinello Greta,Riva Marcello,Branca Antonio,Pizzi Marco,Bonaldi Laura,Martines Annalisa,Manni Sabrina,Visentin Andrea,Trentin Livio,Semenzato Gianpietro,Gurrieri Carmela,Piazza Francesco^ORCID

Funder

Associazione Italiana per la Ricerca sul Cancro

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-020-04178-0.pdf

Reference15 articles.

1. (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood 89(11):3909–3918

2. Sander B, Quintanilla-Martinez L, Ott G, Xerri L, Kuzu I, Chan JK, Swerdlow SH, Campo E (2016) Mantle cell lymphoma--a spectrum from indolent to aggressive disease. Virchows Arch 468(3):245–257. https://doi.org/10.1007/s00428-015-1840-6

3. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390. https://doi.org/10.1182/blood-2016-01-643569

4. Visco C, Finotto S, Zambello R, Paolini R, Menin A, Zanotti R, Zaja F, Semenzato G, Pizzolo G, D’Amore ES, Rodeghiero F (2013) Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol 31(11):1442–1449. https://doi.org/10.1200/JCO.2012.45.9842

5. Tisi MC, Paolini R, Piazza F, Ravelli E, Tecchio C, Sartori R, Famengo B, D’Amore ESG, Carli G, Perbellini O, Di Bona E, Ruggeri M, Visco C (2018) Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma. Am J Hematol 93(12):E386–E389. https://doi.org/10.1002/ajh.25278

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and <i>TP53</i>/p53 – a Nordic Lymphoma Group study;Haematologica;2023-08-31

2. Progress in molecular feature of smoldering mantle cell lymphoma;Experimental Hematology & Oncology;2021-07-13

3. Bortezomib;Reactions Weekly;2020-11